Cantor Fitzgerald analyst Louise Chen maintains $AbbVie (ABBV.US)$ with a buy rating, and adjusts the target price from $200 to $240.
According to TipRanks data, the analyst has a success rate of 41.3% and a total average return of -9.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $AbbVie (ABBV.US)$'s main analysts recently are as follows:
AbbVie's recent report of robust results for Q3 and the subsequent increase in revenue guidance for 2024 contribute to a positive outlook for the company as the year concludes. This optimistic financial trajectory is reflected in the enhanced earnings per share forecast for 2025. Despite this, the assessment of the company's long-term growth prospects in relation to its present market value retains a stance of neutrality.
Following AbbVie's Q3 report, which surpassed expectations and raised future guidance, there is an increase in confidence regarding the company's growth outlook. The revised projections are primarily due to anticipated higher sales of Rinvoq/Skyrizi, though this is somewhat balanced by reduced expectations for aesthetics and Humira sales.
AbbVie has delivered another commendable quarter. The outlook on the shares remains positive, underscored by promising pipeline developments and robust commercial traction looking towards 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
坎托·菲茨杰拉德分析师Louise Chen维持$艾伯维公司 (ABBV.US)$买入评级，并将目标价从200美元上调至240美元。
根据TipRanks数据显示，该分析师近一年总胜率为41.3%，总平均回报率为-9.5%。
此外，综合报道，$艾伯维公司 (ABBV.US)$近期主要分析师观点如下：
艾伯维公司最近报告第三季度强劲业绩，并随后提高了2024年营业收入预期，为年末的公司前景做出了积极贡献。这种乐观的财务发展轨迹体现在2025年每股收益预测的提升上。尽管如此，在评估公司长期增长前景与当前市值的关系时，仍保持中立立场。
在艾伯维公司第三季度报告超出预期并提高未来预期之后，对公司增长前景的信心增强。修订后的预期主要是由于对Rinvoq/Skyrizi销售预期较高，尽管这在一定程度上被美容和Humira销售预期下调所平衡。
艾伯维公司又交出了令人称赞的一个季度。股票前景仍然积极，得益于有望的管道发展和朝2025年望去的强劲商业推动力。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
